Menkes Disease Treatment Market Will Grow At Highest Pace Owing To Rising Orphan Drug Designations
Menkes Disease Treatment Market Will Grow At Highest Pace Owing To Rising Orphan Drug Designations
Menkes disease is an X-linked neurodegenerative disorder caused by mutations in the ATP7A gene

Menkes disease is an X-linked neurodegenerative disorder caused by mutations in the ATP7A gene. Symptoms include sparse, brittle hair; impaired vascular tissue growth; low serum copper levels; and delayed development. Treatment for Menkes disease primarily involves replacement of copper through intravenous administration of copper histidine. Currently, there are only a few FDA-approved treatment options for Menkes disease. Patients primarily rely on off-label use of existing copper histidine products.

The Menkes Disease Market size is estimated to be valued at US$ 165.1 million in 2024 and is expected to exhibit a CAGR of 6.6% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the Menkes disease treatment market are Fortress Biotech, Inc., Teva Pharmaceutical Industries Ltd., Amerigen Pharmaceuticals Limited, Mylan N.V., and Bausch Health Companies Inc. Fortress Biotech launched MNK-6105, a novel formulation of copper histidine for the treatment of Menkes disease in 2020.

The growing diagnosis of Menkes disease, especially in developed regions, is expected to drive the demand for treatment drugs. According to CDC, an estimated 1 in 34,000 to 39,000 newborn males are affected by Menkes disease each year in the United States.

Technological advancements in drug design and manufacturing, such as modified drug delivery systems and novel formulations, are generating lucrative opportunities in the market. Companies are focusing on developing orphan drugs with improved bioavailability and fewer side effects.

Market Trends

Increasing collaborations between biotech companies and research institutes is one of the key trends witnessed in the market. For instance, in 2019 Fortress Biotech partnered with the University of Connecticut to develop treatments for rare genetic disorders like Menkes disease.

Emergence of novel drug formulations is another major trend. MNK-6105 developed by Fortress Biotech is a nano-particle formulation of copper histidine, resulting in enhanced absorption and lowering the dosing frequency.

Market Opportunities

Orphan drug designations by regulatory bodies provide significant market opportunities. Drugs in development for rare diseases like Menkes enjoy benefits like tax credits, waiver of application fees, and market exclusivity for a period of 7 years in the US.

Geographic expansion in developing Asian countries and Latin America presents untapped growth prospects. Availability of low-cost manufacturing infrastructure and emergence of local biotech companies also supports market expansion.

Impact Of COVID-19 On Menkes Disease Market Growth

The outbreak of COVID-19 pandemic has adversely impacted the growth of Menkes disease market globally. Several factors such as restrictions on non-essential medical services, disruptions in supply chain, difficulty in conducting clinical trials, etc contributed to slowed market growth during the crisis. However, with gradual lifting of lockdowns and restoration of healthcare facilities post-recovery from first and second waves, the market is expected to regain lost momentum. Teleconsultations helped to sustain continuity of care for Menkes disease patients during lockdowns. Development of vaccines and treatments have improved disease management, though challenges persist in some geographical regions with limited resources. In the post-pandemic scenario, partnerships involving stakeholders would be pivotal to ensure uninterrupted access to diagnostics and therapeutics. Long-term strategies focusing on decentralized community-based services may help boost early diagnosis and effective treatment interventions.

Menkes Disease Market In North America

North America holds the major share of the Menkes Disease Market in terms of value. This can be mainly attributed to factors such as availability of advanced healthcare infrastructure, growing healthcare expenditure, presence of major market players, and high diagnosis and treatment rates in the region. The United States commands the lion's share within the North America regional market. Favorable reimbursement policies have ensured high adoption of screening and treatment options for Menkes disease. Furthermore, continuous research activities have led to development of new treatment approaches, driving the regional market growth. Other countries in North America such as Canada are also lucrative markets expected to register significant growth over the forecast period.

Fastest Growing Region - Asia Pacific

The Asia Pacific region is poised to witness the fastest growth in the Menkes disease market during the forecast period. This growth can be credited to rising medical tourism, increasing patient population due to growing birth rates, and improving healthcare expenditures in emerging economies of the region. In addition, heightened awareness about early diagnosis and availability of generic medications are supporting the Asia Pacific market expansion. Countries such as China and India with their large population bases and significant improvements in healthcare access present immense growth opportunities. Initiatives by governments towards strengthening newborn screening programs would boost early diagnosis and treatment uptake. Overall, the Asia Pacific Menkes disease market is anticipated to attract higher investments from global players over the coming years.

Get more insights on this topic: https://www.trendingwebwire.com/menkes-disease-market-estimated-to-witness-high-growth-owing-to-advancements-in-gene-therapy/

 

Author Bio

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

What Are The Key Data Covered In This Menkes Disease Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Menkes Disease Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Menkes Disease Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Menkes Disease Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Menkes Disease Market vendors

FAQ’s

Q.1 What are the main factors influencing the Menkes Disease Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Menkes Disease Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Menkes Disease Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

disclaimer

What's your reaction?

Comments

https://www.timessquarereporter.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!

Facebook Conversations